Delay for FDA approval of diabetes drug
13th Nov 2006, 21:29 GMT
It'll take a bit longer than expected for federal regulators to weigh in on a new diabetes drug.
Delay for FDA approval of diabetes drug related news:
- FDA Extends Novartis Drug Review — WSJ.com: What's News Europe
- FDA Decision on Novartis Drug Is Delayed — WSJ.com: What's News Europe
- Novartis diabetes drug faces three month delay — Pharmaceutical Business Review Latest News
- FDA Review on Novartis Galvus Extended — Government/ Industry Regulation News from StratCenter.com
- Novartis diabetes drug delayed — FT.com - Companies
- U.S. delays Novartis diabetes drug — Marketplace by Bloomberg - International Herald Tribune
- FDA Expands Use of Abbott's Humira — Government/ Industry Regulation News from StratCenter.com
- Dendreon completes FDA filing for prostate-cancer drug — The Seattle Times: Horse racing
- North American gets FDA approval for breast cancer treatment — Latest news from Los Angeles Business from bizjournals
- Novartis announces three-month extension of US regulatory review for Galvus® to assess recently available clinical data — WebWire - Recent Headlines
Latest news from WISTV - Health:
- Report: Red meat may increase breast cancer risk
- Health Alert: Stem cell donation
- Health Alert: Reflexology
- FDA proposes "abnormal behavior" warning for Tamiflu label
- Medicare Part 'D' open enrollment begins Nov. 15th
- Study: Patients with obstructive lung diseases get just half the recommended medical care
- Palmetto Health Baptist breaks ground on new expansion, renovation project
- Health Alert: Music for the heart
- Health Tip: Help the Medicine Go Down
- 10% of Americans Struggle With Chronic Pain